Cagrilintide

Cagrilintide is a long-acting synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It is engineered with a fatty-acid side chain that binds serum albumin, extending its half-life to support once-weekly research dosing.

If GLP-1 is the 'I'm not hungry' hormone, amylin is the 'I'm actually full' hormone. Cagrilintide is the long-acting version researchers pair with Semaglutide to hit appetite from two angles at once.

Activates amylin and calcitonin receptors, slowing gastric emptying, suppressing glucagon, and signaling satiety in the hindbrain. Its mechanism is complementary to GLP-1 agonists, which is why combination research has drawn so much attention.

Long-acting amylin analogue. Slows gastric emptying and contributes to satiety via different pathway than GLP-1s.

1. Cagrilintide
2. Incretin and appetite-regulating receptors
3. Slowed gastric emptying and altered satiety signalling
4. Energy-balance and glycaemic research endpoints

A plain-English read on how much published evidence currently exists for Cagrilintide. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of Cagrilintide.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

5mg or 10mg vial

Worked concentration example

5mg + 2mL BAC water → 2.5mg/mL On U-100 insulin syringe:

• • 12 units = 0.3mg (starting)
• • 24 units = 0.6mg
• • 48 units = 1.2mg
• • 96 units = 2.4mg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

Start: 0.3mg weekly. Titrate to 2.4mg weekly.

Commonly cited frequency

Once weekly, subcutaneous

Commonly cited study duration

16–32 weeks. Often run alongside semaglutide.

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Obesity and weight-loss models
• •CagriSema (Cagrilintide + Semaglutide) trials
• •Gastric emptying studies
• •Satiety and food-intake research
• •Combination therapy with GLP-1 agonists

Heavily discussed in GLP-1 communities as the next frontier after Semaglutide and Tirzepatide. The 'CagriSema' combination is the focal point — Phase III data has shown weight-loss percentages competitive with or exceeding Tirzepatide in some endpoints.

“Semaglutide's tag-team partner for appetite.”

The defining stack is Cagrilintide + Semaglutide (CagriSema). Sometimes discussed alongside Tirzepatide as comparators.

Cagrilintide is a long-acting amylin analog studied alongside GLP-1 agonists for additive satiety, gastric slowing, and weight-loss research.